Oral infigratinib in PROPEL 3 shows favorable 52-week trends in children
In PROPEL 3, oral infigratinib treatment for 52 weeks showed favorable trends versus placebo on clinically meaningful exploratory endpoints, including sleep apnea and otitis media events.